Software toolkit shapes models for personalized radionuclide therapy

June 11, 2013

External beam radiation treatment has long been manipulated into the unique shape of patients' tumors for personalized cancer care. Technology providing a means of patient-specific radionuclide drug therapies has not been standardized, as it has been limited to software that requires oncologists to manually define the areas of tumors. A new "phantom" model of the human form that can be deformed and reformed to match anatomy in a matter of hours using 3D graphic design software is being combined with a precision method for predicting how radionuclide therapies interact with tissues to determine the most effective cancer-killing dose for every patient.

"One-size-fits all therapy is not optimal for patients who could be getting personalized ," said Susan Kost, MS, principal author of the study from Vanderbilt University in Nashville, Tenn. "With individualized patient modeling we have an opportunity to offer more aggressive radionuclide therapy. Knowing a patient's drug kinetics and anatomy means we can give the possible while minimizing effects on normal tissue."

The geometric design technology used for these anthropomorphic models, created by Paul Segars, PhD, at Duke University, is called NURBS (non-uniform rational b-splines). With NURBS, anatomical volumes derived from computed tomography imaging data of patients' organs and body parts are sculpted, rotated and scaled to create a model within one to two hours. Once a model is made, it is used for treatment planning in conjunction with single photon emission computed tomography or positron , which—in most cases—use non-therapeutic imaging agents to mimic therapeutic radioactivity in the body. This allows physicians to extrapolate a precise dose, a process called dosimetry, via a 3D map representing projected dose absorption.

Ordinarily, dosimetry is performed by defining the structure and volume of tumors manually in 3D computer programs, known as tumor segmentation. However, this method can be labor intensive and may not provide dose information for normal tissue. In this study, patient-specific NURBS models serve as input in automated dosimetry calculations to factor anatomical data and radiopharmaceutical kinetics for I-131 radioimmunotherapy, specifically looking at the distribution of radioactive particles in the body as they seek out physiological processes of cancer cells and tissues. In action, tumor-tailored monoclonal antibodies are labeled with a potent dose of a radioisotope, and together they bind to receptors on the surface of cancer cells, effectively killing them and sparing nearby healthy cells.

"This research brings nuclear medicine therapy alongside therapy," Kost added. "Now each patient can receive his or her own therapy plan, leading to improved outcomes, better survival rates and less toxicity and harm to normal tissue in the body."

The NURBS phantom models are currently available for clinical use, and Kost expects the modeling toolkit to be used in a subsequent clinical trial conducted by Vanderbilt University for a tumor-targeted peptide receptor radionuclide therapy. A commercially viable version of the dosimetry software is scheduled for release to other cancer centers starting sometime next year.

Explore further: Dose analysis predicts non-Hodgkin lymphoma survival

Related Stories

Dose analysis predicts non-Hodgkin lymphoma survival

June 11, 2013
Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...

Radiopeptide therapy improves survival outcomes for neuroendocrine cancer patients

June 11, 2013
Peptide-receptor radionuclide therapy (PRRT) has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling. A countrywide ...

Cedars-Sinai opens first-of-its-kind trial in western US for metastatic carcinoid cancer patients

June 7, 2013
Working to improve treatment and survivorship outcomes, the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a Phase III clinical trial of targeted radiation for patients with intestinal carcinoid cancer ...

Radioimmunotherapy could extend lives of advanced lymphoma patients

June 11, 2013
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma ...

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

May 21, 2013
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.